Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its gene therapy treatment, ELEVIDYS, during the specified Class Period from June 22, 2023, to June 24, 2025 [1][2]. Group 1: Allegations Against Sarepta - The lawsuit claims that Sarepta made false or misleading statements about the safety risks associated with its gene therapy treatment, ELEVIDYS [2]. - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, which could lead to regulatory scrutiny and halt recruitment and dosing in ongoing trials [2]. - The severity of adverse events from ELEVIDYS treatment is said to have been downplayed, resulting in materially misleading statements from the company [2]. Group 2: Lead Plaintiff Process - Investors in Sarepta have until August 25, 2025, to apply to be appointed as lead plaintiffs, representing the interests of the class in the litigation [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial stake in the case [3]. - Participation as a lead plaintiff does not affect the ability of other investors to share in any potential recovery from the lawsuit [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is the law firm handling the class action and has a reputation for prosecuting class actions and recovering significant amounts for victims of corporate misconduct [4]. - The firm encourages affected investors to reach out for more information regarding the lawsuit [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to significant losses suffered by investors related to the company's product ELEVIDYS, with a deadline for lead plaintiff applications set for August 25, 2025 [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who experienced losses exceeding $100,000 in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Sarepta, alleging violations of federal securities laws, including making false or misleading statements regarding the safety and efficacy of ELEVIDYS [4][9]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Product Safety Issues - The complaint alleges that ELEVIDYS posed significant safety risks, including severe side effects that were not adequately detected during clinical trials [4]. - Following a safety update on March 18, 2025, Sarepta's stock price fell by $27.81 per share, or 27.44%, after a patient died post-treatment with ELEVIDYS [5]. - On April 4, 2025, Sarepta disclosed that regulatory authorities requested a review of the death, leading to a further stock price decline of $4.18 per share, or 7.13% [6]. - A second patient death due to acute liver failure was reported on June 15, 2025, resulting in a significant stock price drop of $15.24 per share, or 42.12% [7][8]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock price decline of $1.52 per share, or 8.01% [8][9].

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. due to alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false statements regarding the safety of its gene therapy ELEVIDYS for Duchenne, which posed significant risks to patients [2] - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, leading to potential regulatory scrutiny and risks regarding the therapy's approvals [2] - The defendants are accused of materially misleading investors and lacking a reasonable basis for their positive statements about ELEVIDYS [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, Inc. related to the safety of its gene therapy ELEVIDYS, alleging that the company and its executives made misleading statements regarding the therapy's risks and trial protocols [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including the gene therapy ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including severe side effects that were not detected during clinical trials [3]. - It is alleged that the severity of adverse events from ELEVIDYS treatment led to the halting of recruitment and dosing in clinical trials, attracting regulatory scrutiny and increasing risks for the therapy's approvals [3]. Key Events Impacting Stock Price - On March 18, 2025, Sarepta reported a patient death due to acute liver failure after ELEVIDYS treatment, causing the stock price to drop over 27% [4]. - Following a disclosure on April 4, 2025, regarding regulatory review of the death, the stock fell more than 7% [5]. - On June 15, 2025, a second patient death was reported, leading to a 42% decline in stock price after Sarepta suspended shipments and paused dosing in clinical studies [6]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, resulting in an additional 8% drop in stock price [7]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of the class [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sarepta Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on August 25, 2025 [1]. Group 1: Class Action Details - Investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 25, 2025 [3]. - The lawsuit alleges that Sarepta made false and misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Specifics - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, which led to adverse events that could impact the therapy's approval and recruitment in clinical trials [5].

Core Viewpoint - A class action has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, during the period from June 22, 2023, to June 24, 2025 [1][2]. Allegations - The complaint alleges that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific incidents include a patient death reported on March 18, 2025, leading to a stock price drop of $27.81 per share (27.44%) to close at $73.54 [3]. - A second patient death due to acute liver failure was disclosed on June 15, 2025, resulting in a further stock price decline of $15.24 per share (42.12%) to close at $20.91 [3]. - Following an FDA investigation announcement regarding acute liver failure risks on June 24, 2025, Sarepta's stock fell by $1.52 per share (8.01%) to close at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file a motion by August 25, 2025, but can remain absent class members without taking action [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Group 1: Allegations - The complaint alleges that during the class period from June 22, 2023, to June 24, 2025, Sarepta Therapeutics made materially false and misleading statements regarding ELEVIDYS [3]. - Specific allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to a halt in trials and increased regulatory scrutiny [3]. Group 2: Shareholder Actions - Shareholders who purchased shares during the specified class period are encouraged to register for the class action, with a deadline of August 25, 2025, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [5].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. concerning allegations of securities fraud and unlawful business practices related to its drug ELEVIDYS [1][2]. Group 1: Lawsuit Details - Investors who purchased Sarepta securities during the Class Period can request to be appointed as Lead Plaintiff by August 25, 2025 [2]. - The lawsuit is based on claims that Sarepta and its officers engaged in fraudulent activities [2]. Group 2: Impact of ELEVIDYS on Stock Price - On March 18, 2025, Sarepta's stock price dropped by $27.81 (27.44%) to close at $73.54 following the announcement of a death related to ELEVIDYS treatment [3]. - Following an April 4, 2025 disclosure regarding a review of the death, the stock fell by $4.18 (7.13%) to close at $54.43 [4]. - A second fatality was reported on June 15, 2025, leading to a significant stock price decline of $15.24 (42.12%) to close at $20.94 [5]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, causing the stock to fall by $1.52 (8.01%) to close at $17.46 [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged misrepresentations regarding the safety risks of its product ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Sarepta and certain senior officers [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by August 25, 2025, with the option to remain as absent class members if they choose not to take action [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its gene therapy product, ELEVIDYS, which poses significant safety risks to patients [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from June 22, 2023, to June 24, 2025 [1]. - Allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to halted recruitment and increased regulatory scrutiny [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 25, 2025, to potentially become lead plaintiffs [2]. - Registration includes enrollment in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Group 3: Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].